December 7, 2010Journal of Clinical OncologyOpen Access

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

View Full Paper

Ask AI

Bookmark

Authors

ALAlbert LaiAPLA Health ATAnh TranVA San Diego Healthcare System PNPhioanh L. NghiemphuUniversity of Minnesota

Abstract

Patients treated with BV and TMZ during and after RT showed improved PFS without improved OS compared to the University of California, Los Angeles/KPLA control group. Additional studies are warranted to determine if BV administered first-line improves survival compared to BV at recurrence.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lai et al. (2010) studied this question.

synapsesocial.com/papers/69dd63ebc5e71f7918100e84 https://doi.org/10.1200/jco.2010.30.2729

View Full Paper

Ask AI

Bookmark

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

Abstract

Discussion

Cite This Study

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

Abstract

Discussion

Cite This Study

Also Consider

Also Consider